EA
PTCT icon

Emerald Acquisition’s PTC Therapeutics PTCT Stock Holding History

Emerald Acquisition’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$394K Sell
28,147
-1,683
-6% -$13.7K ﹤0.01% 2521
2016
Q2 		$209K Buy
+29,830
New +$219K ﹤0.01% 2722

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Emerald Acquisition's PTCT Position: Q3 2016 in Review

Emerald Acquisition reduced its PTC Therapeutics (PTCT) stake by 5.6% in Q3 2016, selling an estimated $13.7K and leaving 28,147 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #2521.

Emerald Acquisition first reported a position in PTCT in Q2 2016 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold PTCT as of Q3 2016.

  • Emerald Acquisition held 28,147 shares of PTC Therapeutics worth $394K as of Q3 2016.
  • Emerald Acquisition sold 1,683 PTC Therapeutics shares in Q3 2016, an estimated $13.7K.
  • PTC Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2521 holding.
  • Emerald Acquisition first reported a position in PTC Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.